• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Asacol (mesalamine) delayed-release tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- September 2009


Summary View



Use in Hepatic Impairment  
  • There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine.  Caution should be exercised when administering Asacol to patients with liver disease.
Information for Patients
  • (reworded) taking care not to break cut, or chew the  tablets, because the coating is an important part of the delayed-release formulation.